Marisa Wexler, MS, senior science writer —

Despite minor improvements in recent years, the availability of care for people with dementia in Europe is largely inadequate, according to a new report. The report, “Dementia Monitor 2020,” was published by Alzheimer Europe, an organization that campaigns to ensure that Alzheimer’s disease and dementia are treated…

People with mild-to-moderate Alzheimer’s disease  treated for three weeks with sargramostim, a medication that activates the immune system, showed improvements in cognition in a small clinical trial. These results support further investigation of sargramostim — and, more generally, the strategy of targeted immune activation — in treating Alzheimer’s, its…

Cassava Sciences plans to launch two Phase 3 clinical trials evaluating the efficacy of simufilam, its investigational oral treatment for Alzheimer’s disease, in the second half of this year, the company announced. If successful, results of these studies in patients with mild-to-moderate disease will…

Simufilam, an investigational oral medication being developed by Cassava Sciences, improved cognition and behavior in people with Alzheimer’s disease after six months of dosing in a clinical trial, interim data show. “Today’s data once again suggests simufilam could be a transformative, novel therapeutic,” Nadav Friedmann, MD, PhD, chief medical…

People with Alzheimer’s disease, as well as their caregivers, are being urged — on social media and via press releases — to get COVID-19 vaccines as soon as possible. That’s the recommendation of the Medical, Scientific and Memory Screening Advisory Board of the Alzheimer’s Foundation of America (AFA). “Getting…

A newly developed technique could make it easier to measure very small concentrations of molecules, which may have implications in early diagnostic testing for Alzheimer’s and other diseases. The technique was described in Research, in the study “Single-Atom Nanozymes Linked Immunosorbent Assay for Sensitive Detection of…

The last participant has completed the planned 24 weeks in the Phase 2 PEGASUS clinical trial, which is assessing the safety and biological activity of Amylyx Pharmaceuticals‘ investigational therapy AMX0035 in people with Alzheimer’s disease. Top-line results from the trial are expected in the first half of…

The U.S. Food and Drug Administration has given clearance for a Phase 2B clinical trial to evaluate the safety, tolerability, and efficacy of Nueraly‘s investigational therapy NLY01 in people with Alzheimer’s disease. The randomized, double-blinded, placebo-controlled trial is expected to enroll more than 500 people with mild…

An advisory arm of the U.S. Food and Drug Administration (FDA) is recommending that available clinical data on aducanumab (BIIB037) does not support the effectiveness of this investigational therapy in treating Alzheimer’s disease.   In votes, eight of the committee’s 11 members found Phase 3 EMERGE data did not…

A first patient has been dosed in a Phase 2 trial evaluating the effects of ALZ-801 on disease-related biomarkers in people with early Alzheimer’s disease, who have a specific genetic variant associated with an increased risk of disease progression. “This biomarker study is a key element of our…